Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Khorana score
immune-checkpoint inhibitors
lung cancer
thromboprophylaxis
venous thrombo-embolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
06
02
2021
received:
20
10
2020
accepted:
12
02
2021
pubmed:
20
2
2021
medline:
22
5
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICI). The Khorana Score (KS), used to guide thromboprophylaxis in cancer patients, was validated in patients receiving chemotherapy. To assess VTE rates and KS performance among NSCLC patients treated with ICI or chemotherapy. We performed a retrospective cohort study of NSCLC patients starting either ICI or platinum-based chemotherapy. The 6-month cumulative incidence of VTE in the ICI and chemotherapy cohorts and hazard ratios (HR) with 95% confidence intervals (CI) were calculated, using death as a competing risk. Subgroup analysis of low (0-1) and high (≥2) KS risk groups was performed. The study included 345 NSCLC patients receiving single agent ICI (n = 176) or chemotherapy (n = 169). The 6-month cumulative incidence of VTE was 7.1% in the chemotherapy cohort and 4.5% in the ICI cohort (HR for chemotherapy = 1.6, 95% CI 0.66-3.9). Among chemotherapy treated patients, the high-risk KS group had a trend toward a higher VTE incidence, compared with patients with a low-risk KS (HR 3.04, 95% CI 0.82-11.22). Among ICI-treated patients, the high-risk KS group had a trend toward a lower VTE incidence compared with the low-risk group (HR 0.17, 95% CI 0.02-1.36). VTE rates were higher among NSCLC patients treated with platinum-based chemotherapy than those treated with ICI alone, though the precision of the relative estimate is low. The KS did not identify high-risk ICI-treated patients, suggesting that an ICI-specific risk model is warranted.
Sections du résumé
BACKGROUND
There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICI). The Khorana Score (KS), used to guide thromboprophylaxis in cancer patients, was validated in patients receiving chemotherapy.
OBJECTIVE
To assess VTE rates and KS performance among NSCLC patients treated with ICI or chemotherapy.
METHODS
We performed a retrospective cohort study of NSCLC patients starting either ICI or platinum-based chemotherapy. The 6-month cumulative incidence of VTE in the ICI and chemotherapy cohorts and hazard ratios (HR) with 95% confidence intervals (CI) were calculated, using death as a competing risk. Subgroup analysis of low (0-1) and high (≥2) KS risk groups was performed.
RESULTS
The study included 345 NSCLC patients receiving single agent ICI (n = 176) or chemotherapy (n = 169). The 6-month cumulative incidence of VTE was 7.1% in the chemotherapy cohort and 4.5% in the ICI cohort (HR for chemotherapy = 1.6, 95% CI 0.66-3.9). Among chemotherapy treated patients, the high-risk KS group had a trend toward a higher VTE incidence, compared with patients with a low-risk KS (HR 3.04, 95% CI 0.82-11.22). Among ICI-treated patients, the high-risk KS group had a trend toward a lower VTE incidence compared with the low-risk group (HR 0.17, 95% CI 0.02-1.36).
CONCLUSIONS
VTE rates were higher among NSCLC patients treated with platinum-based chemotherapy than those treated with ICI alone, though the precision of the relative estimate is low. The KS did not identify high-risk ICI-treated patients, suggesting that an ICI-specific risk model is warranted.
Identifiants
pubmed: 33605020
doi: 10.1111/jth.15272
pii: S1538-7836(22)00750-4
doi:
Substances chimiques
Anticoagulants
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250-1258Informations de copyright
© 2021 International Society on Thrombosis and Haemostasis.
Références
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22(2):199-207. https://doi.org/10.1634/theoncologist.2016-0214
Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850. https://doi.org/10.1056/NEJM200012213432504
Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17-I21. https://doi.org/10.1161/01.CIR.0000078466.72504.AC
Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829. https://doi.org/10.1002/cncr.21496
Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist. 2018;23(2):247-255. https://doi.org/10.1634/theoncologist.2017-0205
Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287. https://doi.org/10.3324/haematol.2018.209114
Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x
Shen Q, Dong X, Tang X, Zhou J. Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case control study. J Thorac Dis. 2017;9(12):5068-5074. https://doi.org/10.21037/jtd.2017.11.116
Peippo MH, Kurki S, Lassila R, Carpén OM. Real-world features associated with cancer-related venous thromboembolic events. ESMO Open. 2018;3(5):e000363. https://doi.org/10.1136/esmoopen-2018-000363
Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30(35):4416-4426. https://doi.org/10.1200/JCO.2012.42.4358
Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy. Anticancer Drugs. 2018;29(6):560-564. https://doi.org/10.1097/CAD.0000000000000625
Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382. https://doi.org/10.1182/blood-2010-02-270116
Agnelli G. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med. 2019;380(8):781-783. https://doi.org/10.1056/NEJMe1816060
Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720-728. https://doi.org/10.1056/NEJMoa1814630
Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711-719. https://doi.org/10.1056/NEJMoa1814468
Wang Y, Wang M, Ni Y, Liang Z. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. Hematology. 2020;25(1):63-70. https://doi.org/10.1080/16078454.2020.1719726
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520. https://doi.org/10.1200/JCO.19.01461
Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772-1778. https://doi.org/10.1111/jth.14564
Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. https://doi.org/10.1056/NEJMoa1507643
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135. https://doi.org/10.1056/NEJMoa1504627
Ettinger DS, Wood DE, Chair V, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 3.2020 Non-Small Cell. Lung Cancer. 2020.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119-iv142. https://doi.org/10.1093/annonc/mdx225
Bar J, Markel G, Gottfried T, et al. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019;120:122-131. https://doi.org/10.1016/j.ejca.2019.06.021
Ibrahimi S, Machiorlatti M, Vesely SK, et al. Incidence of vascular thromboembolic events in patients receiving immunotherapy: a single institution experience. Blood. 2017;130(Supplement 1):4864.
Giustozzi M, Curcio A, Weijs B, et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost. 2020;120(5):847-856. https://doi.org/10.1055/s-0040-1709527
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. https://doi.org/10.1182/blood-2007-10-116327
van Es N, Ventresca M, Di Nisio M, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis. J Thromb Haemost. 2020;18(8):1940-1951. https://doi.org/10.1111/jth.14824
Macbeth F, Noble S, Evans J, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2015;34:1-10.
Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2020. [Epub ahead of print]. https://doi.org/10.1182/blood.2020007878
Sussman TA, Roopkumar J, Li H, et al. Venous thromboembolism (VTE) in melanoma patients on immunotherapy. J Clin Oncol. 2020;38(5_suppl):94.
Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost. 2018;118(9):1668-1678. https://doi.org/10.1055/s-0038-1668523
Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012;13(6):482-487. https://doi.org/10.1016/j.cllc.2012.03.005
Ando Y, Hayashi T, Sugimoto R, et al. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs. 2020;38(4):1200-1206. https://doi.org/10.1007/s10637-019-00881-6
Kunimasa K, Nishino K, Kimura M, et al. Pembrolizumab induced acute thrombosis: a case report. Medicine (Baltimore). 2018;97:e10772.
Gaertner F, Massberg S. Blood coagulation in immunothrombosis-At the frontline of intravascular immunity. Semin Immunol. 2016;28(6):561-569. https://doi.org/10.1016/j.smim.2016.10.010
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-580. https://doi.org/10.1038/s41571-019-0218-0
Khorana AA. Simplicity versus complexity: an existential dilemma as risk tools evolve [published correction appears in Lancet Haematol. Lancet Haematol. 2018;5(7):e273-e274. https://doi.org/10.1016/S2352-3026(18)30067-X
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117(2):219-230. https://doi.org/10.1160/TH16-08-0615
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285. https://doi.org/10.1001/jama.2008.656